Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2396-2410

  Douer, Dan ^a   Tollman, Martin S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; IDARUBICIN; RETINOIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW HYPOPLASIA; BONE MARROW TRANSPLANTATION; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DYSPNEA; ECG ABNORMALITY; FATIGUE; FEVER; FLUID RETENTION; GENERALIZED EDEMA; HEADACHE; HUMAN; HYPOKALEMIA; LEUKOCYTOSIS; LEUKOPENIA; LIVER TOXICITY; LUNG INFILTRATE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCYTOPENIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; BLOOD DISEASE;

ANTINEOPLASTIC AGENTS; ARSENICALS; CLINICAL TRIALS; HEMATOLOGIC NEOPLASMS; HUMANS; OXIDES;

EID: 17144377127     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.217     Document Type: Review

References (95)

1. Antman KH: Introduction: The history of arsenic trioxide in cancer therapy. Oncologist 6:1-2, 2001 (suppl 2)
2. Waxman S, Anderson KC: History of the development of arsenic derivatives in cancer therapy. Oncologist 6:3-10, 2001 (suppl 2)
3. Forkner CE, Scott TFM: Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 97:3-5, 1931
4. Zhang TD: Treatment of acute granulocytic leukemia with "Ai ling No. 1": clinical analysis and experimental research. Chin J Comb Trad West Med 4:19-20, 1984
5. Zhang TD: Leukemia treatment in traditional Chinese medicine. Chin J Traditional Chin Med 10:13-14, 1985
6. Sun H, Ma L, Hu C, et al: Thirty-two cases of treating acute promyelucytic leukemia by ailing-1 (cancer-cure-1) therapy combined with syndrome differentiation treatment of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 12:170-171, 1992
7. Zhang P, Wang SY, Hu LH, et al: Treatment of acute promyelocytic leukemia with arsenic trioxide injection ("713"): Clinical observations and study of action mode. Chin J Hematol 17:58-60, 1996
8. Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360, 1997
9. Zhang P: The use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 13:195-200, 1999
10. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998
11. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001
12. Dombret H, Fenaux P, Soignet SL, et al: Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 39:8-13, 2002 (suppl 1)
13. Niu C, Van H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315-3324, 1999
14. Shalabi AM, Fallavollita A, Cheson BD, et al: Arsenic trioxide in relapsed or refractory acute promyelocytic leukemia: An NCI special exception (compassionate use) program. Blood 98: 596a, 2001 (abstr)
15. Lazo G, Kantarjian H, Estey E, et al: Use of arsenic trioxide (As203) in the treatment of patients with acute promyelocytic leukemia: The M.D. Anderson experience. Cancer 97:2218-2224, 2003
16. Shen Y, Shen ZX, Van H, et al: Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage. Leukemia 15:735-741, 2001
17. Fox E, Adamson PC, Murgo A, et al: Phase I trial and pharmacokinetic study of arsenic trioxide in children with refractory leukemia. Presented at Am Soc Clin Oncol 38th Annual Meeting, Orlando, FL, May 18-21, 2002
18. Cortes JE, Kantarjian H, O'Brien S, et al: All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 73:2946-2952, 1994
19. Thomas X, Dombret H, Cordonnier C, et al: Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation: APL Study Group. Leukemia 14: 1006-1013, 2000
20. Thomas X, Anglaret B, Thiebaut A, et al: Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: The role of all-trans retinoic acid therapy. Ann Hematol 75:195-200, 1997
21. Warrell RP Jr, Maslak P, Eardley A, et al: Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience. Leukemia 8:929-933, 1994
22. Estey EH: Treatment options for relapsed acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:521-534, 2003
23. Lo Coco F, Breccia M, Diverio D: The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:503-520, 2003
24. Fenaux P, Chevret S, Guerci A, et al: Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia: European APL Group. Leukemia 14:1371-1377, 2000
25. Douer D: Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol 107:1-17, 2002
26. Chen ZX, Xue YQ, Zhang R, et al: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413-1419, 1991
27. Tobita T, Takeshita A, Kitamura K, et al: Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90:967-973, 1997
28. Gallagher RE: Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 16: 1940-1958, 2002
29. Degos L, Dombret H, Chomienne C, et al: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643-2653, 1995
30. Grignani F, Fagioli M, Alcalay M, et al: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10-25, 1994
31. Lo Coco F, Diverio D, Pandolfi PP, et al: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 340:1437-1438, 1992
32. Miller WH Jr, Levine K, DeBlasio A, et al: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 82:1689-1694, 1993
33. Douer D, Hu W, Giralt S, et al: Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 8:132-140, 2003
34. Kwong YL, Au WY, Chim CS, et al: Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study. Am J Hematol 66:274-279, 2001
35. Sanz MA, Arcese W, de la Rubia J, et al: Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: A survey of the European blood and marrow transplantation group (EBMT). Blood 96:522a, 2000 (abstr 2247)
36. de Botton S, Fawaz A, Chevret S, et al: Autologous and allogeneic stem cell transplantation (SCT) in second CR (CR2) in acute promyelocytic leukemia (APL) initially treated with ATRA: European APL Group experience. Blood 100:217a, 2002 (abstr 816)
37. Meloni G, Diverio D, Vignetti M, et al: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 90:1321-1325, 1997
38. Leoni F, Gianfaldoni G, Annunziata M, et al: Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: A bridge to transplantation. Haematologica 87:485-489, 2002
39. Estey EH, Giles FJ, Beran M, et al: Experience with gemtuzumab ozogamycin ("Mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99:4222-4224, 2002
40. Mathews V, Balasubramanian P, Shaji RV, et al: Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. Am J Hematol 70:292-299, 2002
41. Ghavamzadeh A, Alimoghaddam N, Aghdami M, et al: Treatment of new cases of acute promyelocytic leukemia by arsenic trioxide. Presented at the Am Soc Clin Oncol 39th Annual Meeting, Chicago, IL, May 31-June 3, 2003
42. Chen GQ, Shi XG, Tang W, et al: Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353, 1997
43. Gianni M, Koken MH, Chelbi-Alix MK, et al: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91:4300-4310, 1998
44. Jing Y, Wang L, Xia L, et al: Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97:264-269, 2001
45. Rego EM, He LZ, Warrell RP Jr, et al: Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 97:10173-10178, 2000
46. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al: Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189: 1043-1052, 1999
47. Raffoux E, Rousselot P, Poupon J, et al: Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21: 2326-2334, 2003
48. Shen ZX, Shi ZZ, Fang J, et al: All-trans retinoic acid/As203 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101:5328-5335, 2004
49. Tallman MS, Nabhan C, Feusner JH, et al: Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 99:759-767, 2002
50. Estey EH, Giles FJ, Kantarjian H, et al: Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 94: 2230-2235, 1999
51. Estey EH, Faderl S, Giles F, et al: All-trans retinoic acid (ATRA) + arsenic trioxide (ATO) to minimize or eliminate chemotherapy in untreated APL. Blood 102:618a-619a, 2003 (abstr 2281)
52. Munshi NC, Tricot G, Desikan R, et al: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16:1835-1837, 2002
53. Hussein MA, Saleh M, Ravandi F, et al: Phase 2 study of arsenic trioxide in patients with relapsed or refractor multiple myeloma. Br J Haematol 125:470-476, 2004
54. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8:3658-3668, 2002
55. Hussein M, Elson P, Reed J, et al: Clinical experience with Trisenox (arsenic trioxide) in combination with ascorbic acid (AA) and dexamethasone (DEX). Presented at the 8th Congress of the European Hematology Association, Lyon, France, June 12-15, 2003
56. List AF, Schiller GJ, Mason J, et al: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary findings in a phase 2 clinical study. Blood 102:423a, 2003 (abstr 1539)
57. Vey N, Dreyfus F, Guerci A, et al: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase 1/2 study. Blood 102:422a-423a, 2003 (abstr 1536)
58. Raza A, Buonamici S, Lisak L, et al: Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy evil expression. Leuk Res 28:791-803, 2004
59. Wang ZG, Rivi R, Delva L, et al: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92:1497-1504, 1998
60. Roboz GJ, Dias S, Lam G, et al: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525-1530, 2000
61. Parmar S, Rundhaugen LM, Boehlke LL, et al: Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 28:909-919, 2004
62. Dai J, Weinberg RS, Waxman S, et al: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268-277, 1999
63. Konig A, Wrazel L, Warrell RP Jr, et al: Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 90:562-570, 1997
64. Zhou Y, Hileman EO, Plunkett W, et al: Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101: 1098-1104, 2003
65. Uslu R, Sanli UA, Sezgin C, et al: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6:4957-4964, 2000
66. Maeda H, Hori S, Nishitoh H, et al: Tumor growth inhibition by arsenic trioxide (As203) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61: 5432-5440, 2001
67. Gallagher R, Ferrari A, Makower D, et al: Pilot results from a phase II trial of arsenic trioxide in hormone-refractory prostate cancer. Cancer Invest 20:84-85, 2002 (abstr 50)
68. Vuky J, Yu R, Schwartz L, et al: Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 20:327-330, 2002
69. Qian J, Qin S, He Z: Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer. Zhonghua Zhong Liu Za Zhi 23:487-489, 2001
70. Ni J, Chen G, Shen Z, et al: Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin Med J (Engl) 111:1107-1110, 1998
71. Vahter M: Mechanisms of arsenic biotransformation. Toxicology 181-182:211-217, 2002
72. Soignet S, Bienvenu B, Warrell RP, et al: Pharmacokinetics of arsenic trioxide (ATO) in patients with relapsed/refractory acute promyelocytic leukemia (APL). Presented at the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, the Netherlands, November 7-10, 2000
73. Soignet S, Bienvenu B, Cheung N-K, et al: Clinical and pharmacologic study of arsenic trioxide (As2O3) in patients with solid tumors. Presented at the Am Soc Clin Oncol 36th Annual Meeting, New Orleans, LA, May 20-23, 2000
74. Zhang X, Cornelis R, de Kimpe J, et al: Study of arsenic-protein binding in serum of patients on continuous ambulatory peritoneal dialysis. Clin Chem 44:141-147, 1998
75. Barbey JT, Pezzullo JC, Soignet SL: Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609-3615, 2003
76. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 350:1013-1022, 2004
77. Malik M, Farbom P, Batchvarov V, et al: Relation between QT and RR intervals is highly individual among healthy subjects: Implications for heart rate correction of the QT interval. Heart 87:220-228, 2002
78. Singer JW, Kirkhart B, Frank K, et al: Safety experience with Trisenox (arsenic trioxide). Blood 102:509b, 2003 (abstr 5767)
79. Singer JW: Cardiac toxicity of arsenic trioxide. Blood 98:1633, 2001
80. Unnikrishnan D, Dutcher JP, Varshneya N, et al: Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97:1514-1516, 2001
81. Westervelt P, Brown RA, Adkins DR, et al: Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98:266-271, 2001
82. Huang SY, Chang CS, Tang JL, et al: Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 103:1092-1095, 1998
83. Grad JM, Bahlis NJ, Reis I, et al: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98:805-813, 2001
84. Camacho LH, Soignet SL, Chanel S, et al: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18: 2620-2625, 2000
85. Miller WH Jr: Molecular targets of arsenic trioxide in malignant cells. Oncologist 7:14-19, 2002 (suppl 1)
86. Miller WH Jr, Schipper HM, Lee JS, et al: Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903, 2002
87. Kitamura K, Minami Y, Yamamoto K, et al: Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14:1743-1750, 2000
88. Jing Y, Dai J, Chalmers-Redman RM, et al: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102-2111, 1999
89. Hayashi T, Hideshima T, Akiyama M, et al: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1:851-860, 2002
90. Lew YS, Brown SL, Griffin RJ, et al: Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59:6033-6037, 1999
91. La Rosee P, Johnson K, O'Dwyer ME, et al: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30:729-737, 2002
92. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
93. O'Dwyer ME, La Rosee P, Nimmanapalli R, et al: Recent advances in Philadelphia chromosome-positive malignancies: The potential role of arsenic trioxide. Semin Hematol 39: 18-21, 2002 (suppl 1)
94. Heredia ZD, Mann KK, Schipper HM, et al: Effect of methylation on the arsenic-mediated apoptosis in APL cells. Blood 100:222b-223b, 2002 (abstr 4405)
95. Chen GQ, Zhou L, Styblo M, et al: Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 63:1853-1859, 2003